Teva MS Drug Patent Backed By UK High Court In Mylan Row

Law360, New York (July 29, 2013, 4:46 PM EDT) -- The U.K. High Court of Justice on Monday affirmed the validity of a Teva Pharmaceutical Industries Ltd. patent for its multiple sclerosis drug Copaxone, ruling the patent would be infringed by generic versions of the drug being developed by Mylan Laboratories Inc.

In a unanimous decision, the appellate court refused a bid by Mylan's Generics (UK) Ltd. unit to revoke Teva's European Patent (UK) 762,888. The decision affirms a ruling issued last year by Justice Richard David Arnold, the head of the U.K.'s patents court....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.